SHANGHAI, April 28, 2024/PRNewswire/ -- On the evening of April 25, the company released its report for the first quarter of 2024. During the reporting period, the company achieved operating income33.0161,000 yuan, up 91.10% year-on-year; Achieved net profit from mother - RMB 102.1366 million; total R&D investment84.646,900 yuan, a year-on-year increase of 94.73%.
Evidence-based medical research continues to advance, and clinical potential is being released at an accelerated pace
The company's first commercial product, contizolamide tablets, is a new generation of oxazolidinone antimicrobials independently designed and developed by the company, which can be used to treat complex skin and soft tissue infections. In 2023, the company achieved revenue of 97.7764 million yuan.
Previously, the company set up a self-operated commercial team of about 100 people in China and operated it for more than three years. In view of the huge potential for the development of the Chinese market, the company is also continuously exploring a complete and diversified commercial promotion model.
After the launch of contizolamide tablets, the company actively promoted clinical studies initiated by many key clinical experts and multiple researchers, and accumulated rigorous and strong evidence-based evidence, laying the foundation for expert consensus and clinical guideline updates.
By the end of 2023, the researchers had initiated a total of 15 post-marketing studies on contezolamide, which had accumulated a large number of successful real-world cases of treatment in the fields of complex skin and soft tissue infections, bloodstream infections, and drug-resistant tuberculosis, showing good safety and efficacy advantages. A total of 23 related articles were published.
With significant clinical application value, contizolamide tablets not only passed municipal expert review and other procedures and were officially included in the “2022 Shanghai Biomedical “New and Excellent Pharmaceutical Device” Product Catalogue, but also successfully included in the “White Paper on Innovative Tuberculosis Diagnosis, Treatment, and Prevention Technology”. In addition, contizolamide tablets have also been included in the classification management catalogue of antimicrobials in 9 provinces (autonomous regions and municipalities directly under the Central Government), including Beijing City and Sichuan Province.
As the clinical value of contizolamide tablets continues to be verified and product accessibility continues to improve, the company's commercialization results in the first quarter were impressive, and the pace of commercialization is expected to accelerate further in 2024.
A variety of drugs are in critical clinical stages, creating a differentiated product pipeline
In addition to the core product contizolamide tablets that have already been marketed for sale, the company is also promoting clinical trials of several products under development domestically and internationally.
In terms of core products, the company is accelerating new indications for contizolamide tablets and clinical trials of MRX-4, consolidating the company's leading position in multi-drug resistant gram-positive antimicrobials. MRX-4 is a water-soluble precursor to contezolamide tablets. It will expand the clinical use scenario of contezolamide tablets. The injection form provides convenience for critically ill patients.
In other clinical phase pipelines, the company has increased R&D deployment and continues to advance clinical trials of MRX-8 and MRX-5, a new drug against drug-resistant gram-negative bacteria. In 2024, the company will begin preparations for the MRX-5 IND application in the US and complete the summary of the MRX-8 Phase I clinical trial in China.
In addition, the company will continue to promote early research and development of peptide drug conjugates and antibody drug conjugates to meet clinical needs for treating kidney disease and solid tumors. At present, peptide drug conjugates and antibody drug conjugate pipelines have completed phased pharmacogenicity studies and applied for a number of patents.
In the future, the company will also continue to build the company's leading position based on the three core technologies suited to its own R&D characteristics, including drug molecular design and discovery technology, and metabolism-based drug design and optimization technology to achieve the company's “acute/chronic infectious diseases+non-infectious diseases” strategic layout.
About Mengke
Established in 2007, it is an innovative biomedical enterprise centered on treating infectious diseases, with global independent intellectual property rights and international competitiveness. It is committed to discovering, developing and commercializing innovative drugs that do not meet clinical needs. Since its inception, the company has been adhering to the concept of “seeking good results with good medicine”, focusing on the increasingly serious problem of bacterial drug resistance around the world, solving clinical problems and differentiated innovation as its core competitiveness. The goal is to provide more effective and safer treatment options for the most common and serious clinically resistant bacterial infections. For more information, please visit the official website of Mengke Pharmaceuticals or subscribe to Mengke Pharmaceuticals China's official WeChat account.